

December 8, 2017

To whom it may concern:

Company Name TOHO HOLDINGS CO., LTD.  
 Corporate Representative Norio Hamada, Chairman of the Board and Representative Director  
 (First Section of Tokyo Stock Exchange Securities Code:8129)  
 Contact: Makoto Kawamura, Corporate Officer, General Manager, Public and Investor Relations Department  
 (TEL: 81-3-6838-2803)

**Notice Regarding Launch of  
 6 Ingredients/ 14 Products of Generic Drugs for KYOSOMIRAI PHARMA**

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; Chairman of the Board and Representative Director: Norio Hamada; hereinafter, “TOHO HOLDINGS”) is pleased to announce that KYOSOMIRAI PHARMA CO., LTD. (Headquarters: Tokyo; President and Representative Director: Atsushi Udoh; hereinafter, “KYOSOMIRAI PHARMA”), the wholly-owned subsidiary involved in pharmaceuticals manufacture and sales business, has launched 6 ingredients/ 14 products of generic drugs today on December 8, 2017 as below.

New products list

Classes	Product Name	Original Brand Name
HMG-CoA Reductase Inhibitor	Rosuvastatin Tablets 2.5mg / 5mg “KYOSOMIRAI”	Crestor Tablets 2.5mg / 5mg
HMG-CoA Reductase Inhibitor	Rosuvastatin OD Tablets 2.5mg / 5mg “KYOSOMIRAI”	Crestor OD Tablets 2.5mg / 5mg
Long Active ARB	Irbesartan Tablets 50mg / 100mg / 200mg “KYOSOMIRAI”	Avapro Tablets / Irbetan Tablets 50mg / 100mg / 200mg
Angiotensin II type 1 (AT1) Receptor Blocker	Olmesartan OD Tablets 5mg / 10mg / 20mg / 40mg “TOWA”	Olmetec OD Tablets(UK)/ Benicar OD Tablets(US) 5mg / 10mg / 20mg / 40mg
Anti-herpesvirus agents	Famciclovir Tablets 250mg “KYOSOMIRAI”	Famvir Tablets 250mg
Acne Vulgaris	Adapalene Gel 0.1% “KYOSOMIRAI”	Differin Gel 0.1%
Leukotriene receptor antagonist / Anti-bronchial Asthma Drug	Montelukast Na Chewable Tablets 5mg “TAKATA”	Kiples Chewable Tablets 5mg / Singulair Chewable Tablets 5mg

## **KYOSOMIRAI PHARMA CO., LTD.**

KYOSOMIRAI PHARMA was established on November 1, 2016 as the wholly-owned subsidiary of TOHO HOLDINGS which engages in business such as pharmaceutical wholesaling, management of pharmacies, and development and provision of customer support systems under the corporate slogan, “Total commitment to good health”. KYOSOMIRAI PHARMA involves in development, manufacture and sales business of prescription pharmaceuticals centered on generic drugs as well as contracted manufacture of them. Establishing a business scheme of integrated manufacture and sales which accurately responds to customers’ demands, KYOSOMIRAI PHARMA aims to stably and effectively provide high quality and high value added prescription pharmaceuticals mainly for generic drugs.

### **【Outline of KYOSOMIRAI PHARMA】**

Company Name	KYOSOMIRAI PHARMA CO., LTD.
Head Office	1-4-4Hiromachi, Shinagawa-ku, Tokyo 140-0005, Japan
Marunouchi Office	GranTokyo South Tower 12F, 1-9-2 Marunouchi, Chiyoda-ku, Tokyo100-6612, Japan
Executives	Representative director and senior advisor: Norio Hamada Representative director and chairman: Ryuzo Takada Representative director and president: Atsushi Udoh
Business Contents	Manufacture and sales of prescription pharmaceuticals, Contracted manufacture of injectable pharmaceuticals